Product Image

Contributor Information

  • Name Malcolm F G Stevens
  • Institute University of Nottingham

Tool Details

  • Tool name: Antitumoral Phortress Small Molecule (Tool Compound)
  • Molecular formula: C20H25Cl2FN4OS
  • Tool type: Small molecules
  • Cancer type: Breast; Ovarian; Renal
  • Description: The Antitumoral Phortress compound is a potential anticancer agent for treatment of human breast carcinoma. Phortress is highly selective for susceptible cancer cells because of its mechanism of action. Following the release of 5F 203 from Phortress, it activates AhR signalling and causes induction of cytochrome P450 activity, which metabolically bioactivates 5F 203 to a cytotoxic species at the tumour site. Phortress (the dihydrochloride salt of the lysylamide prodrug of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203)) is an experimental antitumour agent with potent and selective activity against human-derived carcinomas of breast, ovarian and renal origin The mechanism of action of Phortress is distinct from all classes of chemotherapeutic agents currently in the clinic, and involves metabolic activation by cytochrome P450 (CYP) 1A1 to electrophilic species, which generate DNA adducts in sensitive tumours only.
  • Research area: Cancer ; Cell Cycle ; Epigenetics & Nuclear Signalling

  • For Research Use Only

Target Details

  • Target: Human derived carcinomas of breast, ovarian and renal origin

Application Details


  • Purity: 459.41 g/mol
  • Solubility:
  • Storage conditions:
  • Shipping conditions: Dry Ice


  • Available on request


  •   Bradshaw et al. 2009. Pharmacology. 83(2):99-109. PMID: 19088497.
  •   Preclinical toxicokinetic evaluation of phortress [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride] in two rodent species.
  •   Fichtner et al. 2004. Breast Cancer Res Treat. 87(1):97-107. PMID: 15377855.
  •   The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models.
  •   Bradshaw et al. 2004. Curr Med Chem. 11(8):1009-21. PMID: 15078163.
  •   The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate.